{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:05:52Z","timestamp":1775279152566,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Thymic carcinoids are a rare type of malignant neuroendocrine tumors which have a poor prognosis due to their distant metastasis, invasive behaviour, and postoperative recurrence. Surgical resection is still the fundamental mode for treating thymic carcinoids. Here, we report the rapid shrinkage of an atypical thymic carcinoid with multiple metastases following chemoradiation plus octreotide as a first-line therapy<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 39-year-old Chinese man presented with chest tightness, dyspnea with a history of lumbago and untreated malignant thymoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Thoracic computed tomography (CT) scan revealed an anterior mediastinal mass with pulmonary and multiple bone metastases as well as bilateral pleural and pericardial effusions. Percutaneous needle biopsy was performed on the mediastinal mass and the pathological diagnosis was neuroendocrine carcinoma of moderately differentiation (atypical carcinoid)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The tumor was considered unresectable because of extensive invasion into the lung and various bones. The patient was started on paclitaxel and oxaliplatin per 21 days for 4 cycles, and on 20\u200amg of depot formulation of octreotide once per 21 days. After 2 cycles of chemotherapy, the patient received concurrently mediastinal radiotherapy (39.6 Gy\u200a\u00d7\u200a22 fractions).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>A follow-up CT of the chest at the completion of his fourth chemotherapy regimen demonstrated, approximately 22% of tumor shrinkage. There were no signs of disease progression but the patient refused further chemoradiation treatment. The patient received monthly treatment of octreotide and zoledronate and his progression-free survival reached 18 months. Due to uncontrollable disease progression, the patient expired.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Early diagnosis and radical surgery of thymic carcinoid are very important. However, radiotherapy (combined\/noncombined chemotherapy) must be considered if radical resection is not performed. We believe that further study of chemoradiation and octreotide with the palliative intent of preparing tumors for shrinkage is warranted as a strategy to improve curative management of neuroendocrine tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000013286","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T23:27:05Z","timestamp":1542756425000},"page":"e13286","source":"Crossref","is-referenced-by-count":4,"title":["Metastatic thymic carcinoid responds to chemoradiation and octreotide"],"prefix":"10.1097","volume":"97","author":[{"given":"Zhu","family":"Mei","sequence":"first","affiliation":[{"name":"Department of Oncology, Sir Run Run Hospital, Nanjing Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sir Run Run Hospital, Nanjing Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengnan","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sir Run Run Hospital, Nanjing Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Second Affiliated Hospital of Southeast University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/1097-0142(197204)29:4<1061::AID-CNCR2820290456>3.0.CO;2-3","article-title":"Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases","volume":"29","author":"Rosai","year":"1972","journal-title":"Cancer"},{"key":"R2-20230914","first-page":"35","article-title":"Neuroendocrine neoplasms of the mediastinum","volume":"8","author":"Wick","year":"1991","journal-title":"Semin Diagn Pathol"},{"issue":"(Suppl 2)","key":"R3-20230914","doi-asserted-by":"crossref","first-page":"ii102","DOI":"10.1093\/annonc\/mdn116","article-title":"Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up","volume":"19","author":"Oberg","year":"2008","journal-title":"Ann Oncol"},{"key":"R4-20230914","first-page":"201","article-title":"Carcinoid tumors and oat cell carcinomas of the thymus","volume":"11","author":"Rosai","year":"1976","journal-title":"Pathol Annu"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","article-title":"Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases","volume":"114","author":"Moran","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/jc.2002-021314","article-title":"Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1","volume":"88","author":"Gibril","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11864-008-0080-2","article-title":"Treatment of early stage thymic tumors: surgery and radiation therapy","volume":"9","author":"Gielda","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0025-6196(25)38242-X","article-title":"Carcinoid tumor of the thymus: a clinicopathologic report of seven cases with a review of the literature","volume":"55","author":"Wick","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1378\/chest.124.1.141","article-title":"A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus","volume":"124","author":"Tiffet","year":"2003","journal-title":"Chest"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.COC.0000020584.56294.72","article-title":"Atypical thymic carcinoid and malignant somatostatinoma in type I multiple endocrine neoplasia syndrome: case report","volume":"26","author":"Lin","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000182196","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification","volume":"90","author":"Kloppel","year":"2009","journal-title":"Neuroendocrinology"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/pgmj.67.787.462","article-title":"Giant thymic carcinoid","volume":"67","author":"John","year":"1991","journal-title":"Postgrad Med J"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0003-4975(98)01063-7","article-title":"Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients","volume":"67","author":"Fukai","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1510\/icvts.2010.237651","article-title":"Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation","volume":"11","author":"Dutta","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0003-4975(01)03032-6","article-title":"Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study","volume":"72","author":"Gal","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-2005-837706","article-title":"Multimodality treatment of neuroendocrine tumors of the thymus","volume":"53","author":"Dosios","year":"2005","journal-title":"Thorac Cardiovasc Surg"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/JTO.0b013e31815eb7a2","article-title":"Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report","volume":"3","author":"Dham","year":"2008","journal-title":"J Thorac Oncol"},{"key":"R18-20230914","first-page":"79","article-title":"Advances in the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"3","author":"Kunz","year":"2010","journal-title":"Clin Exp Gastroenterol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pharmthera.2004.02.002","article-title":"Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis","volume":"102","author":"Dasgupta","year":"2004","journal-title":"Pharmacol Ther"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","article-title":"Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours","volume":"37","author":"Aparicio","year":"2001","journal-title":"Eur J Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811210-00038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:23:34Z","timestamp":1775276614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811210-00038"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":20,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013286","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}